Special Issue

SARS-CoV-2 Infections; Treatment and Development of Vaccine

Message from the Guest Editors

The infectuous disease (COVID-19) caused by the novel coronavirus(SARS-CoV-2) is still raging through mutant strains all over the world. In order to deal with this unprecedented situation, therapeutic drugs and vaccines against COVID-19 are being commercialized faster than ever before. Along with changes in infectivity, transmissibility, antigenicity, and pathogeneicity, the efficacy of current vaccines is also of concern in the emergence of mutant strains. Multiple vaccines of different types are currently licenced, including mRNA vaccines, viral vector vaccines, and recombinant protein vaccines. At present, the following factors have been clarified regarding the preventive effects obtained by vaccines and their mechanisms of the action. Neutralizing antibodies against the S protein play an important role in the protective effects induced by commercial vaccines. It is possible that effects other than the neutralizing activity of cell-mediated immunity and humoral immunity also contribute to the preventive effect of vaccines, and these immune responses may affect the lon-term persistence of vaccine efficacy and preventive effects against severe disease.

Guest Editors

Dr. Yasunari Matsuzaka

1. Department of Microbiology and Immunology, Showa Medical University Graduate School of Medicine, Shinagawa-ku, Tokyo 142-8555, Japan
2. Division of Molecular and Medical Genetics, Center for Gene and Cell Therapy, The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo 108-8639, Japan
3. Administrative Section of Radiation Protection, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo 187-8551, Japan

Dr. Ryu Yashiro

Department of Infectious Diseases, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka-shi, Tokyo 181-8611, Japan

Deadline for manuscript submissions

closed (20 October 2024)

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed

mdpi.com/si/151286

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed

mdpi.com/journal/vaccines

About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp
Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).

MDPI